With our in house developed in vitro immunisation process we are able to activate naive B lymphocytes antigen-specifically within 12 days and fuse them afterwards with our transgenic fusion cell line. As a result we can identify hybridoma clones producing antigen-specific human IgM or IgG immunoglobulins. For the selection of desired clones we use selma with an anti-human antibody catcher matrix.
As example to prove the process we used the nucleocapsid protein from SARS-CoV-2 as antigen and stimulated peripheral B lymphocytes according to our protocol. After fusion we were able to detect several specific hybridomas producing nucleocapsid-specific human antibodies.
We performed selma with these hybridomas and could identify suitable candidates producing antibodies specific for the nucleocapsid protein.
Of course we also tried this process with the spike protein of SARS-CoV-2 which worked as well. The specific hybridoma clones were transferred to mass culture and the antibodies will be purified soon. Additionally, the antibody sequences were used to establish a recombinant production of the best performing mAb candidates.